Bladder Cancer Therapeutics and Diagnostics Market - Growth, Trends, COVID-19 Impact, and Forecasts (2022 - 2027)

The Bladder Cancer Therapeutics and Diagnostics Market is Segmented by Product (Therapeutics and Diagnostics), Cancer Type, and Geography.

Market Snapshot

Bladder Cancer Therapeutics and Diagnostics Market Share
Study Period: 2018 - 2026
Base Year: 2021
Fastest Growing Market: Asia Pacific
Largest Market: North America
CAGR: 4 %
Bladder Cancer Therapeutics and Diagnostics Market Key Players

Need a report that reflects how COVID-19 has impacted this market and its growth?

Market Overview

The bladder cancer therapeutics and diagnostics market may witness rapid growth due to the increasing awareness about bladder diseases and available therapies, along with growing healthcare expenditure and the growing burden of bladder cancer. There has been a rapid increase in the overall healthcare expenditure, globally, over the past few years. Therefore, there are new medical technologies, treatments, and medicines available for bladder cancer diseases that contribute majorly to the overall rise in healthcare costs. The high drug prices, drug patent expiry, and cost of healthcare services account for the two-third increase in healthcare spending. The expenditure on increased services, which includes costs of labor and productivity (in biopharmaceutical industries), is also one of the major factors driving healthcare costs.

In addition, the growing research in the development of innovative bladder cancer therapies and the availability of pipeline therapeutics are further propelling the growth of the bladder cancer therapeutics market. Furthermore, the rise in awareness about bladder cancer and its available therapies and the growing smoking and tobacco consumption are also driving the market.

Scope of the Report

As per the scope of the report, bladder cancer is a tumor that starts in the cells of the bladder. Bladder cancer is the rapid, uncontrolled growth of abnormal cells in the urinary bladder lining with epithelial cells. These cancerous cells may even spread through the lining into the muscular wall of the bladder. Several therapies have been developed to treat bladder cancers, which, in turn, build a high demand for the bladder cancer therapeutics market.

By Product
By Therapeutics
Other Therapeuticss
By Diagnostics
Bladder Ultrasound
Other Diagnostics
By Cancer Type
Transitional Cell Bladder Cancer
Squamous Cell Bladder Cancer
Other Cancer Types
By Geography
North America
United States
United Kingdom
Rest of Europe
South Korea
Rest of Asia-Pacific
Middle-East and Africa
South Africa
Rest of Middle-East and Africa
South America
Rest of South America

Report scope can be customized per your requirements. Click here.

Key Market Trends

Cystoscopy is Anticipated to be the Dominant Segment in Diagnostics over the Forecast Period

Cystoscopy is a procedure used to observe the interiors of the bladder and urethra using a telescope. A cystoscope is a specialized endoscope that is inserted through the urethra into the bladder to allow direct visual inspection of the urothelium. Cystoscopy is cost-effective. However, in combination with other tests, its cost can vary. There are approximately 1.2 million flexible cystoscopy procedures conducted annually in the United States. Thus, the introduction of Cysview is boosting the growth of the market, and it is expected to record a higher growth rate during the forecast period. Furthermore, the incidence of bladder cancer is high among the population, which is expected to drive the market over the forecast period.

Bladder Cancer Therapeutics and Diagnostics Market Size

North America Holds the Largest Market Share

The North American region holds the largest share due to rising R&D activities and well-established healthcare infrastructure in the region. Additionally, the presence of a large number of biologics companies and biopharmaceutical companies is contributing to the large size and excellent growth of the bladder cancer therapeutics and diagnostics market.

North America also has the best adoption rates of new diagnostic modalities that are introduced in the commercial space. This trend is in contrast with other regions of the world, where the most widely adopted technologies for cancer diagnostics are at least a decade old. Consequently, North America is a leader in terms of the market size in the bladder therapeutics and diagnostics market.

Bladder Cancer Therapeutics and Diagnostics Market Growth

Competitive Landscape

The major companies active in the market are AstraZeneca, Bristol-Myers Squibb Company, Eli Lilly, GlaxoSmithKline, F. Hoffmann-La Roche Ltd, Novartis, and Pfizer. The companies present in the market are focusing on product innovations, expansions, finding new markets, or innovating their core competencies, in order to expand their market shares.

Table of Contents


    1. 1.1 Study Deliverables

    2. 1.2 Study Assumptions

    3. 1.3 Scope of the Study




    1. 4.1 Market Overview

    2. 4.2 Market Drivers

      1. 4.2.1 Increasing Awareness on Bladder Diseases and Available Therapies

      2. 4.2.2 Increasing Healthcare Expenditure

      3. 4.2.3 Increasing Burden of Bladder Cancer

    3. 4.3 Market Restraints

      1. 4.3.1 Rise in the Number of Patent Expiration and Increased Use of Generic Drugs

      2. 4.3.2 Asymptomatic Nature of the Disease

    4. 4.4 Porter's Five Forces Analysis

      1. 4.4.1 Threat of New Entrants

      2. 4.4.2 Bargaining Power of Buyers/Consumers

      3. 4.4.3 Bargaining Power of Suppliers

      4. 4.4.4 Threat of Substitute Products

      5. 4.4.5 Intensity of Competitive Rivalry


    1. 5.1 By Product

      1. 5.1.1 By Therapeutics

        1. Chemotherapy

        2. Immunotherapy

        3. Other Therapeuticss

      2. 5.1.2 By Diagnostics

        1. Cystoscopy

        2. Bladder Ultrasound

        3. Urinalysis

        4. Other Diagnostics

    2. 5.2 By Cancer Type

      1. 5.2.1 Transitional Cell Bladder Cancer

      2. 5.2.2 Squamous Cell Bladder Cancer

      3. 5.2.3 Other Cancer Types

    3. 5.3 By Geography

      1. 5.3.1 North America

        1. United States

        2. Canada

        3. Mexico

      2. 5.3.2 Europe

        1. Germany

        2. United Kingdom

        3. France

        4. Italy

        5. Spain

        6. Rest of Europe

      3. 5.3.3 Asia-Pacific

        1. China

        2. Japan

        3. India

        4. Australia

        5. South Korea

        6. Rest of Asia-Pacific

      4. 5.3.4 Middle-East and Africa

        1. GCC

        2. South Africa

        3. Rest of Middle-East and Africa

      5. 5.3.5 South America

        1. Brazil

        2. Argentina

        3. Rest of South America


    1. 6.1 Company Profiles

      1. 6.1.1 AstraZeneca PLC

      2. 6.1.2 Bristol-Myers Squibb Company

      3. 6.1.3 Eli Lilly and Company

      4. 6.1.4 F. Hoffmann-La Roche Ltd

      5. 6.1.5 GlaxoSmithKline PLC

      6. 6.1.6 Novartis International AG

      7. 6.1.7 Pfizer Inc.

      8. 6.1.8 Sanofi SA

      9. 6.1.9 Endo Pharmaceuticals Inc.

      10. 6.1.10 Johnson & Johnson (Janssen Pharmaceutical)

    2. *List Not Exhaustive

**Competitive Landscape Covers - Business Overview, Financials, Products and Strategies, and Recent Developments

You can also purchase parts of this report. Do you want to check out a section wise price list?

Frequently Asked Questions

The Bladder Cancer Therapeutics and Diagnostics Market market is studied from 2018 - 2026.

The Bladder Cancer Therapeutics and Diagnostics Market is growing at a CAGR of 4% over the next 5 years.

Asia Pacific is growing at the highest CAGR over 2021- 2026.

North America holds highest share in 2020.

Bristol-Myers Squibb Company, AstraZeneca PLC, GlaxoSmithKline PLC, Johnson & Johnson (Janssen Pharmaceutical), F. Hoffmann-La Roche Ltd are the major companies operating in Bladder Cancer Therapeutics and Diagnostics Market.

80% of our clients seek made-to-order reports. How do you want us to tailor yours?

Please enter a valid email id!

Please enter a valid message!